Latest Oncology News

FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors

FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors

June 27th 2022

Kristi Rosa

The FDA has placed a partial clinical hold on the phase 1/2 NUV-422-02 trial evaluating the selective small molecule CDK2/4/6 inhibitor NUV-422 in patients with solid tumors such as high-grade glioma, hormone receptor–positive advanced breast cancer, and metastatic castration-resistant prostate cancer.

Olaparib Approaches EU Approval for BRCA+, High-Risk Early Breast Cancer

Olaparib Approaches EU Approval for BRCA+, High-Risk Early Breast Cancer

June 27th 2022

Caroline Seymour

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk, early breast cancer who have received neoadjuvant or adjuvant chemotherapy.

Leukemia Pioneers Chronicle Career Experiences and Milestones

Leukemia Pioneers Chronicle Career Experiences and Milestones

June 27th 2022

OncLive Staff

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

June 27th 2022

Jason Harris

The combination of anlotinib and sintilimab was found to provide a long-term survival benefit to patients with previously treated advanced cervical cancer.

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

June 27th 2022

Chris Ryan

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of trastuzumab deruxtecan monotherapy for patients with metastatic HER2-positive breast cancer who have received at least 1 prior anti–HER2-based regimen.

Latest Oncology Videos

All Oncology News

Dr. Kahn on Next Steps on Examining Racial Disparities in GI Cancer

June 15th 2022

Sajid A Khan MD, FACS, FSSO

Sajid A Khan MD, FACS, FSSO, discusses next steps in examining racial disparities in gastrointestinal tract cancer.

Dr. Raje on Current CAR T-Cell Therapies in Multiple Myeloma

June 15th 2022

Noopur S. Raje, MD

Noopur Raje, MD, discusses current CAR T-cell therapies in multiple myeloma.

Dr. Packiam on Safety of Cabazitaxel/Gemcitabine Plus Pembrolizumab in Urothelial Carcinoma

June 15th 2022

Vignesh Packiam, MD

Vignesh Packiam, MD, discusses the adverse effects associated with cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Nivolumab/Ipilimumab and Nivolumab/Chemo Indications Enhance ESCC Treatment Landscape

June 15th 2022

Kyle Doherty

The approval of 2 nivolumab-containing combinations for patients with advanced or metastatic esophageal squamous cell carcinoma have opened the doors for immunotherapy to enter the landscape for this population allowing clinicians options to help patients to meet their individual treatment goals.

Gibney Breaks Down the Evolving Treatment Landscape of Melanoma

June 15th 2022

Ryan Scott

Geoffrey T. Gibney, MD, discusses current treatment options for patients with melanoma, clinical trials that have explored different agents and combinations, and developing treatment options in uveal melanoma.

HR+/HER2- Metastatic Breast Cancer: Treatment Armamentarium

June 15th 2022

Massimo Cristofanilli, MD, FACP

Expert Harold Burstein, MD, PhD, breaks down the treatment armamentarium for patients with HR+/HER2- metastatic breast cancer.

Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan

June 15th 2022

Shanu Modi, MD

Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.

Overview of Basal Cell Carcinoma

June 15th 2022

Jennifer L. Atlas, MD

Shahab Babakoohi, MD, describes the incidence patterns, options for testing and diagnosis, and risk stratification for basal cell carcinoma.

Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer

June 15th 2022

Shanu Modi, MD

Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.

Evolving Treatment Landscape of HR+/HER2- Metastatic Breast Cancer

June 15th 2022

Massimo Cristofanilli, MD, FACP

Massimo Cristofanilli, MD, FACS, provides a historical overview of the HR+/HER2- metastatic breast cancer (mBC) treatment landscape.

Dr. Sandhu on the Safety Data Seen in the MAGNITUDE Trial in Prostate Cancer

June 14th 2022

Shahneen Sandhu, MD

Shahneen Sandhu, MD, discusses the safety data seen in the phase 3 MAGNITUDE trial in metastatic prostate cancer.

Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer

June 14th 2022

Nancy U. Lin, MD

Nancy U. Lin, MD, discusses the advantage of the oral selective estrogen receptor degrader, elacestrant, in ESR1-mutated breast cancers.

Dr. Hamilton on the EMERALD Trial in ER-Positive/HER2-Negative Breast Cancer

June 14th 2022

Erika P. Hamilton, MD

Erika P. Hamilton, MD, discusses the updated analysis of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative breast cancer.

Radiotherapy Use in ATLAS Is Reflective of Current Guidance in High-Risk Localized Prostate Cancer

June 14th 2022

Colleen Moretti

Apalutamide plus androgen deprivation therapy and radiotherapy was evaluated in patients with high- and very high–risk localized or locally advanced prostate cancer, with RT schedules that are reflective of recommended practice guidelines.

State of Science Summit- Women’s Health: Chaired by Robert Wenham, MD, MS, FACOF, FACS

June 14th 2022

State of Science Summit- Women’s Health: Chaired by Robert Wenham, MD, MS, FACOF, FACS

See All News